<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Rebecca J. Abergel | HOPO Therapeutics</title>
    <link>/authors/rebecca-j.-abergel/</link>
      <atom:link href="/authors/rebecca-j.-abergel/index.xml" rel="self" type="application/rss+xml" />
    <description>Rebecca J. Abergel</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>© 2020 HOPO Therapeutics, Inc.</copyright><lastBuildDate>Mon, 01 Jan 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>img/map[gravatar:%!s(bool=false) shape:square]</url>
      <title>Rebecca J. Abergel</title>
      <link>/authors/rebecca-j.-abergel/</link>
    </image>
    
    <item>
      <title>Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents</title>
      <link>/publication/rees-evaluating-2018/</link>
      <pubDate>Mon, 01 Jan 2018 00:00:00 +0000</pubDate>
      <guid>/publication/rees-evaluating-2018/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Toxic heavy metal – Pb, Cd, Sn – complexation by the octadentate hydroxypyridinonate ligand archetype 3,4,3-LI(1,2-HOPO)</title>
      <link>/publication/deblonde-toxic-2018/</link>
      <pubDate>Mon, 01 Jan 2018 00:00:00 +0000</pubDate>
      <guid>/publication/deblonde-toxic-2018/</guid>
      <description></description>
    </item>
    
    <item>
      <title>From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents</title>
      <link>/publication/an-early-2017/</link>
      <pubDate>Sat, 01 Apr 2017 00:00:00 +0000</pubDate>
      <guid>/publication/an-early-2017/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Biodistribution of the Multidentate Hydroxypyridinonate Ligand [ 14 C]-3,4,3-LI(1,2-HOPO), a Potent Actinide Decorporation Agent</title>
      <link>/publication/choi-biodistribution-2015/</link>
      <pubDate>Fri, 01 May 2015 00:00:00 +0000</pubDate>
      <guid>/publication/choi-biodistribution-2015/</guid>
      <description></description>
    </item>
    
    <item>
      <title>In Vitro Metabolism and Stability of the Actinide Chelating Agent 3,4,3-LI(1,2-HOPO)</title>
      <link>/publication/choi-vitro-2015/</link>
      <pubDate>Fri, 01 May 2015 00:00:00 +0000</pubDate>
      <guid>/publication/choi-vitro-2015/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Hydroxypyridinonate Complex Stability of Group (IV) Metals and Tetravalent f-Block Elements: The Key to the Next Generation of Chelating Agents for Radiopharmaceuticals</title>
      <link>/publication/sturzbecher-hoehne-hydroxypyridinonate-2015/</link>
      <pubDate>Wed, 01 Apr 2015 00:00:00 +0000</pubDate>
      <guid>/publication/sturzbecher-hoehne-hydroxypyridinonate-2015/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Analytical Methods for the Bioavailability Evaluation of Hydroxypyridinonate Actinide Decorporation Agents in Pre-Clinical Pharmacokinetic Studies</title>
      <link>/publication/chang-analytical-2013/</link>
      <pubDate>Sun, 01 Dec 2013 00:00:00 +0000</pubDate>
      <guid>/publication/chang-analytical-2013/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Biomimetic Actinide Chelators: An Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)</title>
      <link>/publication/abergel-biomimetic-2010/</link>
      <pubDate>Wed, 01 Sep 2010 00:00:00 +0000</pubDate>
      <guid>/publication/abergel-biomimetic-2010/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
